Drug Trial Radar · NCT07123402
To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
184
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Apr 20, 2026
Study completion May 27, 2026
Sponsor
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- China-Japan Friendship Hospital
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicenter ,randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of TRD205 tablets in the treatment of chronic postoperative neuralgia
Conditions
- Chronic Postoperative Neuralgia
Interventions
TRD205 tabletsDrug
orally ;Take TRD205 1 tablets and Placebo 2 tablets
TRD205 tabletsDrug
orally ;Take TRD205 2 tablets and Placebo 1 tablets
TRD205 tabletsDrug
orally ;Take TRD205 3 tablets and Placebo 0 tablets
PlaceboDrug
orally ;Take Placebo 3 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in the weekly average NRS (numeric pain rating scale,0~10:0 equated to no pain, and 10 equated to the worst pain imaginable )pain score from baseline after 6 weeks of treatmentTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.